With the definition of the minimum inhibitory concentration (MIC; the lowest concentration of the test compound for the specific bioactivity) (Van Dijck et al. 2018), our previous study found that the minimum protective concentration (MPE) for the in vitro model of Parkinson's disease was 0.1 μM for HBP2 and 10 nM for HBP3 (Huang et al. 2024). Here, BBX is linked to Parkinson disease.